Cargando…
Research progress on immunotherapy in triple-negative breast cancer (Review)
Triple-negative breast cancer (TNBC) is a highly heterogeneous and aggressive malignancy. Due to the absence of estrogen receptors and progesterone receptors and the lack of overexpression of human epidermal growth factor receptor 2, TNBC responds poorly to endocrine and targeted therapies. As a neo...
Autores principales: | Zhang, Xiaoxiao, Ge, Xueying, Jiang, Tinghan, Yang, Ruming, Li, Sijie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256074/ https://www.ncbi.nlm.nih.gov/pubmed/35762339 http://dx.doi.org/10.3892/ijo.2022.5385 |
Ejemplares similares
-
Breast osteosarcoma originating from a malignant phyllodes tumor: A case report of a rare neoplasm
por: Jin, Ying, et al.
Publicado: (2021) -
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022) -
Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023) -
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
por: Mediratta, Karan, et al.
Publicado: (2020) -
Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)